1. Home
  2. IFBD vs BCAB Comparison

IFBD vs BCAB Comparison

Compare IFBD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Infobird Co. Ltd

IFBD

Infobird Co. Ltd

N/A

Current Price

$0.92

Market Cap

7.5M

Sector

Technology

ML Signal

N/A

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$3.67

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFBD
BCAB
Founded
2001
2007
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
IFBD
BCAB
Price
$0.92
$3.67
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
147.9K
48.4K
Earning Date
05-01-2023
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.86
EPS
N/A
N/A
Revenue
N/A
$300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.12
52 Week High
$2.18
$6.52

Technical Indicators

Market Signals
Indicator
IFBD
BCAB
Relative Strength Index (RSI) 48.72 48.67
Support Level $0.88 $3.24
Resistance Level $1.13 $6.33
Average True Range (ATR) 0.22 0.37
MACD -0.01 0.02
Stochastic Oscillator 9.13 45.46

Price Performance

Historical Comparison
IFBD
BCAB

About IFBD Infobird Co. Ltd

Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: